631 related articles for article (PubMed ID: 19369690)
1. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
2. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
6. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
7. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.
Zitt E; Jäger C; Rosenkranz AR; Eigner M; Kodras K; Kovarik J; Graf H; Pétavy F; Horn S; Watschinger B
Wien Klin Wochenschr; 2011 Jan; 123(1-2):45-52. PubMed ID: 21253777
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
9. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
11. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
16. Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.
Spiegel DM; Casey L; Bell S; Parker M; Chonchol M
Hemodial Int; 2006 Oct; 10 Suppl 2():S24-7. PubMed ID: 17022747
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
19. "Real-World" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study.
Vervloet M; Bencova V; Malberti F; Ashman N; Os I; Saha H; Ureña P; Zitt E; Rix M; Ryba M; Fouque D; Dehmel B; Petavy F; Jacobson SH
Clin Nephrol; 2010 Sep; 74(3):198-208. PubMed ID: 20860904
[TBL] [Abstract][Full Text] [Related]
20. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
